Joint Centre of Translational Medicine, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang 325000, China.
Joint Centre of Translational Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China.
ACS Appl Bio Mater. 2024 Nov 18;7(11):7684-7699. doi: 10.1021/acsabm.4c01157. Epub 2024 Nov 6.
The prolonged existence of chronic wounds heightens the risk of patients experiencing chronic pain, necrosis, and amputation. Dental pulp stem cells (DPSCs) have garnered attention due to their potential immunomodulatory and tissue repair regenerative effects in the management of chronic wounds. However, stem-cell-based therapy faces challenges such as malignant differentiation, immune rejection, and long-term effectiveness. To overcome these challenges, we proposed a chronic wound therapy using a hydrogel derived from human-originated dental pulp stem cell lysate (DPSCL). Our data indicate that, with the degradation of the dental pulp stem cell lysate-based hydrogel (DPSCLH), the slowly released cell lysates recruit anti-inflammatory M2 macrophages and promote the proliferation, migration, and keratinization of HacaT cells. In addition, studies revealed that DPSCLH avoids immune rejection reactions and induces a long-term accumulation of endogenous M2 macrophages. In a mouse model of diabetic wounds, DPSCLH effectively modulates the inflammatory microenvironment around diabetic wounds, promotes the formation of the stratum corneum, and facilitates the healing of wounds, thus holding tremendous potential for the treatment of diabetic wounds.
慢性创面的长期存在会增加患者发生慢性疼痛、坏死和截肢的风险。牙髓干细胞(DPSCs)因其在慢性创面管理中的潜在免疫调节和组织修复再生作用而受到关注。然而,基于干细胞的治疗方法面临着恶性分化、免疫排斥和长期效果等挑战。为了克服这些挑战,我们提出了一种使用源自人牙髓干细胞裂解物(DPSCL)的水凝胶的慢性创面治疗方法。我们的数据表明,随着牙髓干细胞裂解物基水凝胶(DPSCLH)的降解,缓慢释放的细胞裂解物招募抗炎 M2 巨噬细胞,并促进 HacaT 细胞的增殖、迁移和角化。此外,研究表明 DPSCLH 可避免免疫排斥反应,并诱导内源性 M2 巨噬细胞的长期积累。在糖尿病创面的小鼠模型中,DPSCLH 可有效调节糖尿病创面周围的炎症微环境,促进角质层形成,并促进创面愈合,因此在治疗糖尿病创面方面具有巨大的潜力。